<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468596</url>
  </required_header>
  <id_info>
    <org_study_id>AGN_2014-20</org_study_id>
    <nct_id>NCT02468596</nct_id>
  </id_info>
  <brief_title>Use of QTRAC Technique to Measure Axonal Excitability in Anti-MAG Neuropathy</brief_title>
  <acronym>EXCIMAG</acronym>
  <official_title>Axonal Excitability Measured by QTRAC Technique in Patients With Anti-MAG Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The QTRAC method is an electrophysiological technique that assesses peripheral nerve axonal
      excitability, using computerized analysis of the muscular response of musculus abductor
      pollicis brevis, to series of electrical stimulations of the median nerve.

      Because of its high sensitivity to small changes in axonal excitability, QTRAC may help
      improve the follow-up of patients suffering from peripheral neuropathy caused by
      anti-myelin-associated-glycoprotein antibodies (anti-MAG neuropathy), as axonal excitability
      is early affected in this disease.

      The main aim of the study is to compare QTRAC results in anti-MAG neuropathy patients, with
      QTRAC results in healthy persons (matched for sex and age).

      A secondary aim is to determine whether or not the disease's clinical severity (measured by
      quantitative clinical scores) is correlated with the results of the QTRAC and could be
      predicted by a model based on the several parameters measured in the QTRAC exploration.

      100 anti-MAG neuropathy patients will undergo a QTRAC exploration and a thorough neurological
      examination with clinical scoring. The results will be compared with data (matched by sex and
      age) from the reference database on healthy subjects, that is provided with the QTRAC
      software.

      The investigators expect to prove that QTRAC results are modified in anti-MAG neuropathy
      patients, and that the clinical severity of the disease can be predicted by a combination of
      QTRAC-measured parameters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTRAC-measured refractority of the median nerve</measure>
    <time_frame>Inclusion</time_frame>
    <description>the duration of the refractory period of the median nerve (expressed in milliseconds) is automatically measured by the QTRAC system, using a series of double electrical stimulations (the first being supra-maximal and the second, sub-maximal) and progressively increasing the time between the two stimuli.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peripheral Neuropathy Associated With Anti-myelin Associated Glycoprotein Antibodies (Anti-MAG Neuropathy)</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients suffering from anti-MAG neuropathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QTRAC assessment</intervention_name>
    <description>Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical assessment of peripheral nerve function</intervention_name>
    <description>Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anti-MAG neuropathy (peripheral neuropathy and IgM monoclonal gammopathy with anti-MAG
             activity superior to 1000 BTU)

        Exclusion Criteria:

          -  current treatment with a medication that modifies peripheral nerve excitability (e.g.
             anticonvulsivants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine Gueguen, MD</last_name>
    <phone>+33 1 48 03 67 55</phone>
    <email>agueguen@fo-rothschild.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Neurologie Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guilhem Sole, MD</last_name>
      <phone>+33557821380</phone>
      <email>guilhem.sole@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie Hôpital Henry Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain Crréange, MD</last_name>
      <phone>+33149812310</phone>
      <email>creange@univ-paris12.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Neurologie Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud Lacour, MD</last_name>
      <phone>+33 3 20 44 57 65</phone>
      <email>Arnaud.Lacour@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>service de neurologie, CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent MAGY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service ENMG et pathologies Neuro Musculaires, Hôpital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Vial, MD</last_name>
      <phone>+33472357164</phone>
      <email>Christophe.vial@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laboratoire des explorations fonctionnelles, Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armelle Magot, MD</last_name>
      <phone>+33240083617</phone>
      <email>Armelle.magot@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Gueguen, MD</last_name>
      <phone>+33143086755</phone>
      <email>agueguen@fo-rothschild.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie CHU St Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe Camdessanche, MD</last_name>
      <phone>+33477127805</phone>
      <email>j.philippe.camdessanche@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2015</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Axonal excitability</keyword>
  <keyword>Neuropathy</keyword>
  <keyword>QTRAC</keyword>
  <keyword>anti-MAG</keyword>
  <keyword>Electrophysiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

